Gut microbiome and atrial fibrillation-results from a large population-based study.

Humans Atrial Fibrillation / etiology Gastrointestinal Microbiome Heart Bacteria / genetics Aging Incidence
Atrial fibrillation Epidemiology Gut microbiome Metagenomics

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
May 2023
Historique:
received: 03 10 2022
revised: 26 03 2023
accepted: 06 04 2023
medline: 15 5 2023
pubmed: 30 4 2023
entrez: 29 4 2023
Statut: ppublish

Résumé

Atrial fibrillation (AF) is an important heart rhythm disorder in aging populations. The gut microbiome composition has been previously related to cardiovascular disease risk factors. Whether the gut microbial profile is also associated with the risk of AF remains unknown. We examined the associations of prevalent and incident AF with gut microbiota in the FINRISK 2002 study, a random population sample of 6763 individuals. We replicated our findings in an independent case-control cohort of 138 individuals in Hamburg, Germany. Multivariable-adjusted regression models revealed that prevalent AF (N = 116) was associated with nine microbial genera. Incident AF (N = 539) over a median follow-up of 15 years was associated with eight microbial genera with false discovery rate (FDR)-corrected P < 0.05. Both prevalent and incident AF were associated with the genera Enorma and Bifidobacterium (FDR-corrected P < 0.001). AF was not significantly associated with bacterial diversity measures. Seventy-five percent of top genera (Enorma, Paraprevotella, Odoribacter, Collinsella, Barnesiella, Alistipes) in Cox regression analyses showed a consistent direction of shifted abundance in an independent AF case-control cohort that was used for replication. Our findings establish the basis for the use of microbiome profiles in AF risk prediction. However, extensive research is still warranted before microbiome sequencing can be used for prevention and targeted treatment of AF. This study was funded by European Research Council, German Ministry of Research and Education, Academy of Finland, Finnish Medical Foundation, and the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, and the Paavo Nurmi Foundation.

Sections du résumé

BACKGROUND BACKGROUND
Atrial fibrillation (AF) is an important heart rhythm disorder in aging populations. The gut microbiome composition has been previously related to cardiovascular disease risk factors. Whether the gut microbial profile is also associated with the risk of AF remains unknown.
METHODS METHODS
We examined the associations of prevalent and incident AF with gut microbiota in the FINRISK 2002 study, a random population sample of 6763 individuals. We replicated our findings in an independent case-control cohort of 138 individuals in Hamburg, Germany.
FINDINGS RESULTS
Multivariable-adjusted regression models revealed that prevalent AF (N = 116) was associated with nine microbial genera. Incident AF (N = 539) over a median follow-up of 15 years was associated with eight microbial genera with false discovery rate (FDR)-corrected P < 0.05. Both prevalent and incident AF were associated with the genera Enorma and Bifidobacterium (FDR-corrected P < 0.001). AF was not significantly associated with bacterial diversity measures. Seventy-five percent of top genera (Enorma, Paraprevotella, Odoribacter, Collinsella, Barnesiella, Alistipes) in Cox regression analyses showed a consistent direction of shifted abundance in an independent AF case-control cohort that was used for replication.
INTERPRETATION CONCLUSIONS
Our findings establish the basis for the use of microbiome profiles in AF risk prediction. However, extensive research is still warranted before microbiome sequencing can be used for prevention and targeted treatment of AF.
FUNDING BACKGROUND
This study was funded by European Research Council, German Ministry of Research and Education, Academy of Finland, Finnish Medical Foundation, and the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, and the Paavo Nurmi Foundation.

Identifiants

DOI: 10.1016/j.ebiom.2023.104583 PMID: 37119735 PMC: PMC10165189
pubmed: 37119735
pii: S2352-3964(23)00148-2
doi: 10.1016/j.ebiom.2023.104583
pmc: PMC10165189
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104583

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests RK has received consulting fees from GenCirq Inc, DayTwo Ltd and JGilbert Consulting LLC, payment for lectures from BP Technology Ventures Inc and Hamilton College, support for attending meetings and/or travel from the Chilean Senate, the University of Melbourne, the Shenzhen Society of Science and Technology, the Norwegian Institute of Public Health and participated on a data safety monitoring board for Diversigen, GenCirq Inc, DayTwo Ltd, Cybele Microbiome Inc, BiomeSense Inc, Micronoma Inc. He owns stocks or stock options from Biota Technology Inc, Diversigen, GenCirq Inc Cybele Microbiome Inc and Micronoma Inc. RBS has received lecture fees and advisory board fees from BMS/Pfizer outside this work. TN received payment for lectures or presentations from Servier. JGS occasionally perform bioinformatics consulting for research group in the field of microbiome science via the Center for Microbiome Innovation and Clarity Genomics. VS has ongoing research collaboration with Bayer Ltd., unrelated to the present study.

Auteurs

Joonatan Palmu (J)

Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Turku, Finland; Department of Internal Medicine, Turku University Hospital and University of Turku, Finland.

Christin S Börschel (CS)

Department of Cardiology, University Heart and Vascular Centre Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.

Alfredo Ortega-Alonso (A)

Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Turku, Finland; Neuroscience Center, University of Helsinki, Helsinki, Finland; Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

Lajos Markó (L)

Experimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin and the Max-Delbrück Center, Berlin, Germany; Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany.

Michael Inouye (M)

Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Pekka Jousilahti (P)

Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Turku, Finland.

Rodolfo A Salido (RA)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA.

Karenina Sanders (K)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA.

Caitriona Brennan (C)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA.

Gregory C Humphrey (GC)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA.

Jon G Sanders (JG)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA; Cornell Institute for Host-Microbe Interaction and Disease, Cornell University, Ithaca, NY, USA.

Friederike Gutmann (F)

Experimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin and the Max-Delbrück Center, Berlin, Germany; Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany.

Dominik Linz (D)

Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Centre for Heart Rhythm Disorders, Royal Adelaide Hospital, and University of Adelaide, Adelaide, Australia; Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands.

Veikko Salomaa (V)

Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Turku, Finland.

Aki S Havulinna (AS)

Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Turku, Finland; Institute for Molecular Medicine Finland, FIMM - HiLIFE, Helsinki, Finland.

Sofia K Forslund (SK)

Experimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin and the Max-Delbrück Center, Berlin, Germany; Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany; Structural and Computational Biology, European Molecular Biology Laboratory, Heidelberg, Germany.

Rob Knight (R)

Center for Microbiome Innovation, Jacobs School of Engineering, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Computer Science & Engineering, University of California San Diego, La Jolla, CA, USA; Department of Bioengineering, University of California, San Diego, La Jolla, USA.

Leo Lahti (L)

Department of Computing, University of Turku, Turku, Finland.

Teemu Niiranen (T)

Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Turku, Finland; Department of Internal Medicine, Turku University Hospital and University of Turku, Finland.

Renate B Schnabel (RB)

Department of Cardiology, University Heart and Vascular Centre Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany. Electronic address: r.schnabel@uke.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Gut microbiome and atrial fibrillation-results...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Troubles du rythme cardiaque › Fibrillation auriculaire › Gut microbiome and atrial fibrillation-results...
questionsmedicales.fr › Environnement et santé publique › Environnement › Écosystème › Biodiversité › Biote › Microbiote › Microbiome gastro-intestinal › Gut microbiome and atrial fibrillation-results...
questionsmedicales.fr › Système cardiovasculaire › Coeur › Gut microbiome and atrial fibrillation-results...
questionsmedicales.fr › Bactéries › Gut microbiome and atrial fibrillation-results...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Vieillissement › Gut microbiome and atrial fibrillation-results...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Gut microbiome and atrial fibrillation-results...